Matt Hancock hails ‘good news’ on the Janssen COVID-19 vaccine
Johnson and Johnson, a medical device company, has become the latest firm to come forward with a successful vaccine candidate. Their Jenssen jab followed Novovax yesterday in offering a unique approach to inoculation. Preliminary results showed their vaccine provides a high degree of protection with just a single shot.
Where is the Johnson and Johnson Covid vaccine made?
Like every pioneering vaccine and Covid treatment so far, the Johnson and Johnson jab comes from international labour.
The firm has headquarters in the US, and its subsidiary Janssen has taken up manufacturing duties.
Janssen is based in the Netherlands and tested the jab in several different countries.
We will use your email address only for sending you newsletters. Please see our Privacy Notice for details of your data protection rights.
Trials took place in the UK, US, South Africa and Latin America, and each nation returned different results.
For example, in the US cohort of study participants, the vaccine candidate was 72 percent effective.
With all three continents considered, efficacy rates dropped down to 66 percent.
The candidate was also 85 percent effective in preventing “severe disease” across all regions studied.
Although it wasn’t developed in the UK like the Novavax jab, the UK Government has ordered 30 million doses.
The vaccine’s single-dose delivery should also help other, less well off countries order stocks as well.
They only require fridge-temperature storage, rather than the specialised refrigeration needed of the Pfizer or Moderna jabs.
The cost is also considerably lower, with prices marked at $10 (£7) per dose.
Fraudster dressed as nurse tries to con pensioner into taking fake jab – PICTURES
Is the EU going to take some of the UK’s Covid vaccine supply? – EXPLAINER
EU goes quiet on jab developer it gave £70m to before AstraZeneca row – INSIGHT
Dr Mathai Mammen, Global Head of Janssen Research and Development, spoke about the jab’s international application.
In a statement, he said the Janssen vaccine could reach “as many people as possible”.
Dr Mammen said: “These results are a testament to the extraordinary efforts of everyone involved in our COVID-19 vaccine candidate clinical program, and we are extremely grateful to the clinical trial staff and trial participants for their invaluable contributions.
“Changing the trajectory of the pandemic will require mass vaccination to create herd immunity, and a single-dose regimen with fast onset of protection and ease of delivery and storage provides a potential solution to reaching as many people as possible.”
“The ability to avoid hospitalisations and deaths would change the game in combating the pandemic.”
The Johnson and Johnson vaccine adds another vital jab to the world’s growing arsenal.
With the Pfizer, Moderna, AstraZeneca and soon Novovax vaccines, world governments can pick from seven.
But Novovax and Johnson and Johnson’s jab still require approval from the Medicines and Healthcare products Regulatory Agency (MHRA).
Source: Read Full Article